We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Antibodies|
|Epitope||Extracellular Domain Alternatives|
|Conjugate||This TNFRSF10B antibody is conjugated to PE Alternatives|
Flow Cytometry (FACS)
|2 references available|
|Supplier||Log in to see|
Product Details anti-TNFRSF10B AntibodyTarget Details TNFRSF10B Application Details Handling References for anti-TNFRSF10B antibody (ABIN192359) Images
|Specificity||The antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).|
|Immunogen||Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.|
|Plasmids, Primers & others|
Target Details TNFRSF10BProduct Details anti-TNFRSF10B Antibody Application Details Handling References for anti-TNFRSF10B antibody (ABIN192359) Images back to top
|Alternative Name||CD262 / TRAIL-R2 (TNFRSF10B Antibody Abstract)|
|Background||TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L). Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.|
|Pathways||p53 Signaling, Apoptosis, Positive Regulation of Endopeptidase Activity|
Application DetailsProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Handling References for anti-TNFRSF10B antibody (ABIN192359) Images back to top
|Application Notes||The reagent is designed for Flow Cytometry analysis.Suggested working dilution is 5 µg/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.|
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
|Restrictions||For Research Use only|
HandlingProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Application Details References for anti-TNFRSF10B antibody (ABIN192359) Images back to top
|Buffer||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15 mM sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
Do not freeze.
Avoid prolonged exposure to light.
|Storage Comment||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
References for anti-TNFRSF10B antibody (ABIN192359)Product Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Application Details Handling Images back to top
|Product cited in:||
Vondálová Blanárová, Jelínková, Szöor, Skender, Soucek, Horváth, Vaculová, Andera, Sova, Szöllosi, Hofmanová, Vereb, Kozubík: "Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway." in: Carcinogenesis, Vol. 32, Issue 1, pp. 42-51, 2010
Corallini, Milani, Nicolin, Secchiero: "TRAIL, caspases and maturation of normal and leukemic myeloid precursors." in: Leukemia & lymphoma, Vol. 47, Issue 8, pp. 1459-68, 2006
ImagesProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Application Details Handling References for anti-TNFRSF10B antibody (ABIN192359) back to top